Guidelines for management of chronic obstructive pulmonary disease (COPD) primarily focus on the prevention of weight loss, while overweight and obesity are highly prevalent in patients with milder stages of COPD. This cross-sectional study examines the association of overweight and obesity with the prevalence of comorbid disorders and prescribed medication for obstructive airway disease, in patients with mild to moderate COPD. Data were used from electronic health records of 380 Dutch general practices in 2014. In total, we identified 4938 patients with mild or moderate COPD based on spirometry data, and a recorded body mass index (BMI) of ≥21 kg/m. Outcomes in overweight (BMI ≥ 25 and <30 kg/m) and obese (BMI ≥30 kg/m) patients with COPD were compared to those with a normal weight (BMI ≥ 21 and <25 kg/m), by logistic multilevel analyses. Compared to COPD patients with a normal weight, positive associations were found for diabetes, osteoarthritis, and hypertension, for both overweight (OR: 1.4-1.7) and obese (OR: 2.4-3.8) patients, and for heart failure in obese patients (OR: 2.3). Osteoporosis was less prevalent in overweight (OR: 0.7) and obese (OR: 0.5) patients, and anxiety disorders in obese patients (OR: 0.5). No associations were found for coronary heart disease, stroke, sleep disturbance, depression, and pneumonia. Furthermore, obese patients were in general more often prescribed medication for obstructive airway disease compared to patients with a normal weight. The findings of this study underline the need to increase awareness in general practitioners for excess weight in patients with mild to moderate COPD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700136 | PMC |
http://dx.doi.org/10.1038/s41533-017-0065-3 | DOI Listing |
COPD
December 2025
Division of Respirology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Background: Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.
Methods: We conducted a systematic review of MEDLINE, EMBASE, and Cochrane CENTRAL from inception to July 17, 2024, to identify randomized trials of biologic medications in patients with COPD.
J Multimorb Comorb
January 2025
Trinity Health of New England, St. Francis Hospital, Hartford, CT, USA.
Background: Since comorbid conditions are frequently present in chronic obstructive pulmonary disease (COPD) and affect outcome, a composite scoring system to quantify comorbidity might be helpful in assessing mortality risk.
Methods: We tested the hypothesis that the Charlson Comorbidity Index (CCI) score at the time of an outpatient medical clinic encounter for COPD predicts all-cause mortality. Cox Proportional Hazards analyses were used in 200 randomly selected patients to relate CCI scores to all-cause mortality out to 5 years.
Cureus
December 2024
Internal Medicine, Mercy Health St. Vincent Medical Center, Toledo, USA.
We present a case of spontaneous hemorrhage in an emphysematous bulla, complicated by anticoagulation. Bullous emphysema is a well-recognized complication of chronic obstructive pulmonary disease (COPD), and a rare manifestation is hemorrhage into preexisting pulmonary bullae. A 69-year-old male patient presented to the emergency department with hemoptysis, shortness of breath, and productive cough.
View Article and Find Full Text PDFNiger Med J
January 2025
Department of Epidemiology & Community Health, University of Ilorin, Nigeria.
Background: Sleep is a very important physiologic process which is necessary to maintain a state of well-being. Obstructive Sleep Apnea (OSA) is prevalent among all age groups with variations in presentation and severity. It is often underreported, especially among young people in the Low- and Middle-Income Countries LMICs.
View Article and Find Full Text PDFIndian J Occup Environ Med
December 2024
Department of Electronics, Sri Venkateswara College, University of Delhi, New Delhi, India.
Introduction: Construction sites generate high levels of air pollution, contributing to more than 4% of particulate matter in the atmosphere. Literature indicates that on-site pollution is an important factor that contributes to lung impairments in construction workers. Chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ADRS) are known to be exacerbated because of exposure to a variety of construction pollutants mainly particulate matter (PM10, PM2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!